Does the choice of primary immunosuppression influence the prevalence of cardiovascular risk factors after liver transplantation?
Guckelberger
O
O
Virchow Clinic, Department of Surgery, Berlin, Germany.
Langrehr
J M
JM
Bechstein
W O
WO
Neuhaus
R
R
Luesebrink
R
R
Lemmens
H P
HP
Kratschmer
B
B
Jonas
S
S
Knoop
M
M
Neuhaus
P
P
D015415:Biomarkers; D002318:Cardiovascular Diseases / Q000097:blood / Q000453:epidemiology*; D003430:Cross-Sectional Studies; D016572:Cyclosporine / Q000009:adverse effects*; D005500:Follow-Up Studies; D006801:Humans; D006943:Hyperglycemia / Q000453:epidemiology; D006973:Hypertension / Q000453:epidemiology; D015228:Hypertriglyceridemia / Q000453:epidemiology; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016031:Liver Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D009765:Obesity / Q000453:epidemiology; D015995:Prevalence; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D015996:Survival Rate; D016559:Tacrolimus / Q000009:adverse effects*
D015415:Biomarkers; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D016559:Tacrolimus